2026-01-12
SHENZHEN, December 2025 – During the Fifth Frontiers of Brain Science and Industry Conference and the 2025 Shenzhen Brain-Computer Interface Expo, Blue Ocean Capital officially announced the establishment of its RMB 160 million (US$23 million) Brain Science Seed Fund. This specialized fund is designed to accelerate the transformation of breakthrough research into market-ready solutions, focusing on the most promising frontiers of life science technologies.
The RMB 160 million fund, in strategic corporation with Brain Cognition and Brain Disease Institute of the Shenzhen Institute of Advanced Technlogy (SIAT),one of the research flagship of the Chinese Academy of Sciences (CAS), is supported by a powerful network of strategic partners and investors including Shenzhen Angel FOF, Guangming Science City Development Group, and Luye Pharma (02186.HK), the leading pharmaceutical company in China.
“We are so grateful for the strong support from our strategic partners, investors and cooperators” stated by Frank Yang, the CEO of Blue Ocean Capital during the keynote address. " The Seed Fund is critical to turning breakthrough brain science, BCI technology and other life science innovation into clinic and commercial stage. We are committed to being the scientist's first institutional investor and partner”.
The fund targets early-stage enterprises and source innovations within Brain-Computer Interface (BCI), neuroscience, and broader life science sectors, including Biotech, MedTech, and HealthTech. By focusing on the "embryonic stage" of development—where technical paths are pioneering and yet to be fully proven—the fund aims to catalyze "0 to 1" breakthroughs that possess the potential to redefine medical paradigms.
Blue Ocean Capital identifies and backs disruptive technologies that move beyond traditional treatments toward microscopic, precise, and programmable diagnostics and therapies. Beyond brain-computer interfaces (BCI) and neuroscience, the fund will explore synergies with micro-nano medical robots, gene editing, and AI-driven drug discovery.
A core pillar of this new fund is its commitment to being the "Scientist's First Institutional Investor and Partner". The fund specializes in Seed and Angel rounds, providing more than just financial backing. Through an "Investment-Incubation" integrated model, the firm offers to help scientists and portfolio companies with multiple round funding, team building, corporate strategy, and ecosystem access to bridge the gap between the laboratory and the market , and cross the "Death Valley" of technology transfer.
Blue Ocean Capital, together with the Blue Ocean Brain Science Seed Fund are dedicated to turning breakthrough scientific research into commercial reality to fulfil the Unmet medical needs, ensuring that life-changing technologies reach the patients who need them most.
